NeuroMetrix shares gain after it announces a distribution deal in China for its NC-stat DPNCheck diabetic peripheral neuropathy device.
NeuroMetrix (NSDQ:NURO) said it inked a deal with Omron Medical Devices, a subsidiary of Omron Healthcare China, for the distribution rights to NeuroMetrix's NC-stat DPNCheck in China.
Shares of NeuroMetrix fall more than 4% despite narrower 3rd-quarter losses as investors react to a more than 25% top-line slide.
NeuroMetrix (NSDQ:NURO) shares lost more than 4% of their value yesterday after the medical device company reported a more than 25% sales slide during the 3rd quarter.
NeuroMetrix wins FDA clearance to market its Sensus neurostimulation device for pain management during sleep.
NeuroMetrix's (NSDQ:NURO) Sensus wearable pain management device can now be paired with pajamas thanks to the FDA's clearance of the device for use during sleep.
Delcath Systems announces that it will lay off about 20% of its U.S. employees and redouble its efforts in Europe.
Queensbury, N.Y.-based Delcath (NSDQ:DCTH) announced last week that it plans to pare its workforce by about 20%, the latest in a series of layoff announcements from the oncology devices maker. This is the 3rd time this year that Delcath has announced imminent layoffs, having announced smaller cuts in April and larger layoffs in January.
Greatbatch merges its sales, marketing and operations with subsidiary Electrochem in the interest of shifting from sub-assemblies to complete medical devices, raising its 2013 per-share earnings guidance.
Texas medical device maker Greatbatch (NYSE:GB) raised its 2013 per-share earnings guidance as it announced new efforts to reorganize some of its business practices and reduce costs as it shifts from a components and sub-assemblies company to a developer of full medical devices.
The FDA OKs NeuroMetrix's Sensus pain management system for the U.S. market.
NeuroMetrix (NSDQ:NURO) landed FDA clearance for its Sensus pain management system, a non-invasive transcutaneous electrical nerve stimulator designed to relieve the symptoms of diabetic neuropathy.
Shares of medical device company iCad soar nearly 36% on a Medicare reimbursement nod.
iCad (NSDQ:ICAD) shares nearly doubled their value on Wall Street today after the medical device company said the Centers for Medicare & Medicaid approved a big increase in the reimbursement rate for its Xoft Axxent brachytherapy device.